当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Zokinvy
申请企业
EIGER BIOPHARMACEUTICALS INC
承诺描述
A clinical trial to assess the effect of concomitant administration of a CYP2C9 inhibitor on the pharmacokinetics of lonafarnib. Design and conduct the trial in accordance with the FDA guidance for industry Clinical Drug Interaction Studies-Cytochrome P450 Enzyme- and TransporterMediated Drug Interactions (January 2020).